of Amperio Project in Switzerland and Quitérios in Portugal
Legrand (Paris:LR) is actively pursuing its targeted development strategy, with the announcement today of two new acquisitions.
Amperio Project is a Swiss specialist in busbars. Based in Murten, the company employs around 20 people and has annual sales of over €4 million. Following Computer Room Solutions (CRS) in Australia and Linkk Busway Systems in Malaysia, Amperio Project is the third acquisition of the year in datacenters.
Quitérios 1 is a leading Portuguese player in electrical and digital modular distribution boards. Based in Mira, the company employs more than 100 people and has annual sales of nearly €20 million.
Benoît Coquart, Legrand's Chief Executive Officer; commented:
'We are very pleased with these two new acquisitions, which bring the number of transactions announced since the beginning of the year to five, for a total annual revenue of more than €100 million. These investments are fully in line with our strategic roadmap for 2030, which includes strengthening our positions in fast-growing segments related to the energy and digital transition.'
Readers are invited to verify the authenticity of Legrand press releases with the CertiDox app. Learn more at www.certidox.com
Key financial dates :
• 2025 first-half results :
July 31, 2025
'Quiet period 2 ' starts :
July 1, 2025
• 2025 nine months results :
'Quiet period 2 ' starts :
October 7, 2025
Expand
About Legrand
Legrand is the global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for residential, commercial, and datacenter markets makes it a benchmark for customers worldwide.
The Group harnesses technological and societal trends with lasting impacts on buildings with the purpose of improving life by transforming the spaces where people live, work and meet with electrical, digital infrastructures and connected solutions that are simple, innovative and sustainable.
Drawing on an approach that involves all teams and stakeholders, Legrand is pursuing a strategy of profitable and responsible growth driven by acquisitions and innovation, with a steady flow of new offerings that include products with enhanced value in use (energy and digital transition solutions: datacenters, digital lifestyles and energy transition offerings).
Legrand reported sales of €8.6 billion in 2024. The company is listed on Euronext Paris and is a component stock of the CAC 40, CAC 40 ESG and CAC Transition Climat indexes. (code ISIN FR0010307819).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
Sauer Brands Announces Executive Appointments to Support Continued Growth
RICHMOND, Va.--(BUSINESS WIRE)--Sauer Brands, Inc., a leading food company, today announced key leadership appointments that will support the Company's continued robust growth, expanded distribution, and strategic transformation: Jeremiah Ashukian has been appointed Chief Financial Officer, effective July 14; Wendy Fiel joined as General Counsel, effective June 30; Tom Lee has been named Chief Strategy and Transformation Officer, effective July 14. These three executives will report directly to CEO Yuri Hermida and join the Executive Leadership Team, working alongside senior leaders Clay Matthews (Chief Operating Officer), Brad Wile (Chief Growth Officer), Paula Benedetto (Chief Sales Officer), and April Timmons (Chief People Officer). These appointments come as Sauer Brands continues to invest in people, brands, and capabilities to meet increasing consumer demand across its product portfolio, which includes brands like Duke's Mayo, Mateo's Salsa and Kernel Season's, as well as other flavor-enhancing products distributed nationally through retail and foodservice channels. 'We are thrilled to welcome Jeremiah, Wendy, and Tom to Sauer Brands at such a pivotal time,' said Yuri Hermida, CEO of Sauer Brands. 'As we scale our business and accelerate strategic investments, having world-class leaders with deep industry experience and functional expertise is critical. Jeremiah, Wendy, and Tom are exactly the kind of proven, people-first leaders who will help us sustain our momentum and build for the future.' Ashukian brings more than 20 years of financial leadership experience in the consumer food industry. Most recently, he served as Executive Vice President and Chief Financial Officer at Krispy Kreme, where he helped drive global financial performance and expansion. Prior to that, he spent over two decades at Mars, holding CFO roles across North and South America in the confectionery segment. Throughout his career, he has led high-impact financial initiatives that enabled sustained growth, operational excellence and value creation. Fiel brings more than 20 years of legal leadership experience in the consumer goods sector and as a litigator in private practice. Most recently, she served as Chief Legal Officer and Corporate Secretary at Sabra Dipping Company, where she established and led the legal department and provided strategic counsel across the business, including marketing, human resources, quality and food safety, and procurement. Prior to Sabra, she held senior legal roles at Heineken USA and The Nature's Bounty Co., where she supported major brand portfolios and innovation teams. Her expertise spans legal strategy, compliance, and risk management in fast-paced, regulated environments. Lee brings more than 20 years of experience in strategy, M&A, and corporate finance. Most recently, he served as Senior Vice President of Strategy and M&A at Sovos Brands, where he led enterprise-wide initiatives focused on growth and value creation, helping build the company's strategic platform and contributing to its successful sale to Campbell's in March 2024. Prior to Sovos Brands, he spent ten years at J.P. Morgan as a senior investment banker advising clients in the consumer sector on strategic M&A and capital markets transactions. About Sauer Brands Sauer Brands, Inc. is a privately held, high-growth food company with a portfolio of beloved brands and a mission to 'Make Life Taste Better.' Headquartered in Richmond, Virginia, the company is known for its commitment to flavor, quality, and innovation across a wide range of condiments, spices, sauces, and more. Sauer Brands is backed by Advent International.
Business Wire
40 minutes ago
- Business Wire
Best's Special Report: Individual Annuity Surrenders Dent Operating Profitability
BUSINESS WIRE)--Increasing surrenders on individual annuities drove a 27% decline in pre-tax net operating profitability despite record sales in recent years, according to a new AM Best report. The Best's Special Report, 'Individual Annuity Surrenders Dent Operating Profitability,' states that surrenders increased by 21% to $280 billion in 2024, up from $232 billion in 2023, as higher interest rates and policyholders' desire for better performing products have led to the uptick. Overall, the individual annuity composite's net operating gain fell to $14.9 billion in 2024, compared with $20.5 billion in 2023. 'With the heightened surrender activity over the last few years, the industry now has nearly half of its individual annuity reserves within surrender charge protection or can't be surrendered at all, compared with an average of 37% between 2014-2021,' said Kaitlin Piasecki, industry research analyst, Industry Research and Analytics, AM Best. On the heels of strong momentum in 2023, annuity sales were solid in 2024, led by variable annuity products such as RILAs. The rapid growth has heightened competition, including new private equity/asset manager-owned insurers looking to capitalize on the difference between the cost of liabilities (i.e., crediting rates on products) and potential investment returns. Many companies in the individual annuity composite also have been utilizing reinsurance to manage their growth and capital levels. According to the report, in the last five years, the amount of reserves ceded to reinsurers has increased by 86%, with the biggest portion moving offshore to affiliates. Private equity/asset manager-owned insurers are the lead drivers behind these assets moving offshore. These companies also drive the trend of utilizing offshore affiliates for reinsurance. 'Ceding to offshore affiliated reinsurers allows insurers to manage capital, transfer risk and save on taxes, but AM Best believes that this reduces transparency and is generally a credit negative for the market,' said Jason Hopper, associate director, Industry Research and Analytics, AM Best. 'Private equity/asset manager-owned insurers now account for about one-quarter of the companies in the individual annuity market, nearly one-third of gross premium written in 2024, but also more than half of the reserves ceded.' The report notes that insurers with private equity/asset manager parents have higher allocations to private placements, asset-backed securities, mortgage loans and affiliated investments than other organizational structures. Insurers also have increased allocations to private credit, which allows for flexibility of structures, although these instruments are bespoke, less transparent and less liquid, which results in a higher risk premium for investors. Looking ahead, while annuity companies' investment incomes were in a favorable position at the beginning of 2025, yields have since declined and equity markets have given back some of their previous returns as economic uncertainty has grown. To access the full copy of this special report, please visit
Business Wire
an hour ago
- Business Wire
Elucid Appoints Dr. Robert Pelberg as New Senior Vice President of Medical Affairs
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has named Dr. Robert 'Bob' Pelberg as its new senior vice president of medical affairs. A highly accomplished cardiologist and nationally recognized expert in cardiovascular computed tomography angiography (CCTA), Dr. Pelberg brings to Elucid decades of clinical experience and a deep understanding of advanced imaging technologies and clinical research. In his new role, he will help shape and execute the company's clinical and research strategies and will lead the company's clinical operations quality efforts, ensuring compliance to the highest clinical quality and regulatory standards. 'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians." Share Dr. Pelberg's hiring comes at a pivotal moment for Elucid, as it accelerates both its clinical research strategy and commercial growth of its flagship product PlaqueIQ TM image analysis software. PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology rather than subjective CCTA visual estimates. PlaqueIQ quantifies and classifies plaque morphology based on ground-truth histology, the gold standard for characterization of plaques. The software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk. 'Dr. Pelberg's appointment marks a critical step in Elucid's mission to deliver clinically valuable and scientifically rigorous tools to physicians. He will play a key role in expanding awareness of the company's software and key features within the medical community—engaging with clinicians, guiding study design, and articulating the clinical value of Elucid's histology-based technology in improving cardiovascular care, with our plaque analysis software today and our FFR-CT product in the near future,' said Kelly Huang, CEO of Elucid. 'Together, we are committed to helping align product development with real-world clinical needs, ultimately enhancing the impact of Elucid's work in transforming diagnostics for coronary artery disease.' Dr. Pelberg is board certified in cardiovascular diseases, cardiac CT angiography, nuclear cardiology and echocardiography. He is a fellow of the American College of Cardiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology and the Society of Cardiovascular Computed Tomography. He is also the author and co-author of numerous books as well as clinical publications in the field of cardiac CT. With extensive leadership experience directing cardiovascular service line clinical operations, he most recently served as a clinical cardiologist and advanced cardiac imager at The Christ Hospital Heart and Vascular Institute. 'As physicians, we know the importance of having a clear understanding of each patient's coronary plaque and how that impacts their risk of future cardiac events, including heart attack and stroke, as well as how to care for each individual based on their own plaque assessment. I share Elucid's vision of a future where physicians will be able to incorporate patient specific plaque characteristics to create personalized care pathways in coronary artery disease that can ultimately help reverse the prevalence of heart attack and stroke,' said Dr. Pelberg. 'I look forward to contributing to the company's mission and helping deliver on that goal.' About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
